Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00477425
Status:
WITHDRAWN
Last Update Posted:
2017-05-15
First Post:
2007-05-21
Brief Title:
A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab
Status:
WITHDRAWN
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a supplemental study designed to evaluate the effect of bevacizumab on QTc interval in cancer patients Patients who have consented to participate in selected randomized controlled bevacizumab clinical trials will be invited to participate in this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None